Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TWST News 17 December 2025 - 2 February 2026

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
2 February 2026
·····
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

New York, Jan 12, 2026, 13:43 EST — Regular session Shares of Twist Bioscience Corp jumped roughly 8% Monday following a preliminary first-quarter revenue report that beat expectations. The synthetic DNA company’s stock climbed 7.8% to $38.07 in afternoon trading, trading between $34.51 and $39.80 earlier in the session. The timing is key. Firms are releasing early results just as investors swarm the JPMorgan Healthcare Conference week, and traders are quick to jump on any sign that demand stayed strong through year-end. For Twist, this flash update gives a quick snapshot of spending on synthetic DNA and sequencing prep tools,
12 January 2026
···
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) is ending 2025 with something investors in “tools + genomics” names haven’t always been able to count on: momentum that’s tied to multiple moving pieces—new product launches, partner-driven workflow wins, and a profitability narrative that’s finally getting sharper edges. On December 22, 2025, TWST shares were trading around $34.26, up about 5.4% on the session at the time of writing (midday U.S. trading). MarketScreener That pop isn’t happening in a vacuum. Over the past few weeks, the company has stacked up incremental catalysts—from a fresh licensing deal touching NGS and hot-start PCR, to product expansion
22 December 2025
·····
Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) is drawing fresh attention on Wednesday, December 17, 2025, as the stock trades sharply higher amid a mix of new partnership-related headlines, recent product launches, and updated Wall Street price targets. At the same time, investors are weighing Twist’s push toward higher gross margins and management’s goal to reach adjusted EBITDA breakeven by fiscal Q4 2026—a key milestone in the company’s multi-year path from high-growth to sustainable profitability. SEC Below is a comprehensive, publication-ready roundup of the most current TWST news, forecasts, and analyst commentary available as of 17.12.2025, plus the key datapoints to watch
17 December 2025
·····

Stock Market Today

Nebius (NBIS) stock jumps 16% into weekend as AI trade whipsaws; earnings next week in focus

Nebius (NBIS) stock jumps 16% into weekend as AI trade whipsaws; earnings next week in focus

7 February 2026
Nebius shares jumped 16.6% to $86.10 on Friday, rebounding from a 10.3% drop Thursday. The company will report fourth-quarter and full-year 2025 results before the market opens on Feb. 12. U.S. jobs and inflation data are due next week after a delay from a government shutdown. Recent swings in Nebius stock followed volatility in AI-linked tech names after Alphabet’s spending update.
Go toTop